MedTrace Logo

Vaccine Immune Recovery After Leukemia

NCT05622682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2026-01-26

Study results available
· View outcomes & findings →

Summary

This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia (ALL). Several children's hospitals in the United States are participating in the study, which will enroll up to 100 pediatric participants. The study is intended to determine the rate of infection after leukemia treatment and to inform future studies and recommendations about whether children and adolescents who have leukemia should receive additional vaccine doses or boosters after treatment.

Conditions

  • Acute Lymphoblastic Leukemia, Pediatric

Interventions

OTHER

Observational only: Serology and flow cytometry for ALL cohort participants

Blood samples from ALL cohort participants will be tested to measure antibodies to vaccine-preventable diseases and immune recovery

OTHER

Observational only: Infection rates

Number of infections during the study period will be obtained and infection incidence rates calculated during the first year off-chemotherapy.

Sponsors & Collaborators

Principal Investigators

  • Brian T Fisher, DO MSCE MPH · Children's Hospital of Philadelphia

Eligibility

Min Age
3 Years
Max Age
31 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-28
Primary Completion
2025-10-31
Completion
2025-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05622682 on ClinicalTrials.gov